Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Investig Clin Urol. 2017 Jun;58(Suppl 1):S38-S45. doi: 10.4111/icu.2017.58.S1.S38. Epub 2017 Jun 2.
Since the U.S. Food and Drug Administration approved dextranomer/hyaluronic acid copolymer (Deflux) for the treatment of vesicoureteral reflux, endoscopic injection therapy using Deflux has become a popular alternative to open surgery and continuous antibiotic prophylaxis. Endoscopic correction with Deflux is minimally invasive, well tolerated, and provides cure rates approaching those of open surgery (i.e., approximately 80% in several studies). However, in recent years a less stringent approach to evaluating urinary tract infections (UTIs) and concerns about long-term efficacy and complications associated with endoscopic injection have limited the use of this therapy. In addition, there is little evidence supporting the efficacy of endoscopic injection therapy in preventing UTIs and vesicoureteral reflux-related renal scarring. In this report, we reviewed the current literature regarding endoscopic injection therapy and provided an updated overview of this topic.
自美国食品和药物管理局批准葡聚糖/透明质酸共聚物（Deflux）用于治疗膀胱输尿管反流以来，使用 Deflux 的内镜注射治疗已成为开放式手术和持续抗生素预防的热门替代方法。使用 Deflux 进行内镜矫正具有微创、耐受性好的特点，其治愈率接近开放式手术（即，在几项研究中约为 80%）。然而，近年来，对尿路感染（UTI）的评估方法不够严格，以及对与内镜注射相关的长期疗效和并发症的担忧，限制了这种治疗方法的应用。此外，几乎没有证据支持内镜注射治疗预防尿路感染和膀胱输尿管反流相关肾瘢痕形成的疗效。在本报告中，我们回顾了有关内镜注射治疗的现有文献，并对该主题进行了更新概述。
